Vertex强调非阿片类止痛药Inspirnavx的医疗补助覆盖范围不断扩大

2025-11-12 02:01

Vertex Pharmaceuticals CEO Reshma Kewalramani said that the company has gained Medicaid coverage approval for its non-opioid pain drug Journavx (suzetrigine) in 18 states.
Speaking at the UBS Global Healthcare conference in Palm Beach, FL, the exec said that Vertex is aiming for Medicaid coverage of the medication for moderate-to-severe acute pain in all 50 states.
Kewalramani added that the company is in "advanced" discussions with a large pharmacy benefit manager for coverage.
Approved in January, Journavx is a highly selective NaV1.8 pain signal inhibitor considered non-addictive.
Takeup of the drug has been hampered by its relatively high list price of $15.50 per pill. Normal prescribing calls for two pills per day. In the nine months ended on Sept. 30, Journavx brought in $32.9M in revenue.
In its Q3 earnings call earlier this month, Chief Commercial Officer Duncan McKechnie said more than 300,000 Journavx prescriptions were filled as of mid-October.

More on Vertex Pharmaceuticals